

Tumor Treating Fields (TTFields) in glioblastoma: A Force for Change

🕒 Friday, 25 March 2022

[Click here to save the date!](#)

📅 18:30 – 19:30 KST / 10:30 – 11:30 CET / 05:30 – 06:30 EDT

Speakers



David Tran (Chair)
Gainesville, FL, USA



Michael D. Story
Dallas, TX, USA



Michael Sabel
Düsseldorf, Germany

Agenda

- 18:30 – 18:35** **Welcome and introduction**
David Tran
- 18:35 – 18:45** **Disruptive technology: How do TTFields work?**
Michael D. Story
- 18:45 – 19:00** **Optune®: An established treatment for patients with glioblastoma**
David Tran
- 19:00 – 19:15** **Clinical insights: Expert perspectives on the use of Optune in glioblastoma**
Michael Sabel
- 19:15 – 19:25** **Optune in the real-world: The patient experience**
Jeanneane, Optune patient ambassador
- 19:25 – 19:30** **Summary and close**
David Tran

Indications for Use

Optune is intended as a treatment for adult patients with histologically-confirmed glioblastoma multiforme (GBM). Optune with temozolomide is indicated for the treatment of adult patients with newly diagnosed glioblastoma following maximal debulking surgery, and completion of radiation therapy together with concomitant standard of care chemotherapy.

Select Important Safety Information

Contraindications

Do not use Optune in patients with an active implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. Use of Optune together with implanted electronic devices has not been tested and may theoretically lead to malfunctioning of the implanted device. Use of Optune together with skull defects or bullet fragments has not been tested and may possibly lead to tissue damage or render Optune ineffective. Do not use Optune in patients that are known to be sensitive to conductive hydrogels. In this case, skin contact with the gel used with Optune may commonly cause increased redness and itching, and rarely may even lead to severe allergic reactions such as shock and respiratory failure.

Select Warnings and Precautions

The most common ($\geq 10\%$) adverse events involving Optune in combination with temozolomide were thrombocytopenia, nausea, constipation, vomiting, fatigue, medical device site reaction, headache, convulsions, and depression. The most common ($\geq 10\%$) adverse events seen with Optune monotherapy were medical device site reaction and headache.

Please see Optune Instructions For Use (IFU) for complete information regarding the device's indications, contraindications, warnings, and precautions at [Optune.com/Safety](https://www.optune.com/Safety).

novocure Satellite symposium sponsored by Novocure®